Neuronetics stock gained 1.85 percent after Q2 revenue beat

Published on 10/06/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock's Q2 revenue reached USD 41.57 million on October 2, 2026, beating estimates by 3.20 percent. Adjusted loss narrowed to USD 0.05 per share.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics stock (ISIN US64131A1051) was last at USD 2.20 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, up 1.85 percent from the prior session. The companys latest quarterly report showed revenue growth and a smaller adjusted loss, giving the stock a concrete operating benchmark after a volatile year.

Q2 revenue beat estimates

Zacks reported on October 2, 2026 that Neuronetics generated USD 41.57 million in revenue for the quarter ended June 2026. That was 9.1 percent above the USD 38.11 million recorded a year earlier and 3.20 percent above consensus.

The adjusted loss came to USD 0.05 per share, compared with a consensus loss of USD 0.11 and a year-ago adjusted loss of USD 0.15. The 54.55 percent earnings surprise matters because revenue growth alone has not yet translated into adjusted profitability.

Analysts see wider upside

Ground News reported that BTIG reaffirmed a Buy rating on Neuronetics and set a USD 6.00 price target. The call places emphasis on the companys ability to convert expanding treatment activity into durable earnings.

A separate consensus published by Rallies listed a Buy rating from 2 analysts and an average target of USD 5.50. Compared with the USD 2.20 last price on October 5, 2026, that average target lies 150 percent above the price.

Stock remains below yearly high

The USD 2.20 last price stood 36.0 percent below the 52-week high of USD 3.44 and USD 1.40 above the 52-week low of USD 0.80. Volume reached 810,227 shares, while market capitalization stood at USD 153.1 million on October 5, 2026.

Neuronetics describes NeuroStar as its flagship transcranial magnetic stimulation system for mental health treatment, with more than 4.8 million treatment sessions delivered, according to the companys investor-relations page. The operating question is whether the Q2 revenue gain can continue while the adjusted loss narrows further.

Neuronetics stock stays below USD 3.44

Neuronetics stock was last at USD 2.20 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with the 52-week range at USD 0.80 to USD 3.44. The market capitalization was USD 153.1 million.